{"links":{"feed":"https://www.erudio.com/reports/neo-healer-nct06747338/feed.json","html":"https://www.erudio.com/reports/neo-healer-nct06747338","json":"https://www.erudio.com/reports/neo-healer-nct06747338.json","markdown":"https://www.erudio.com/reports/neo-healer-nct06747338.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"neo-healer-nct06747338"}},"request":"https://www.erudio.com/contact?report=neo-healer-nct06747338"},"offer":{"cited_clinicians":7,"cited_commentary_sources":21,"verified_hcp_statements":104,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":15},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"neo-healer-nct06747338"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=neo-healer-nct06747338","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/neo-healer-nct06747338","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 104 verified statements · 13 from 7 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T20:48:19.477781Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":20,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":15,"title":"Primary endpoint: tpCR (BIRC, AJCC 8th)"},{"claim_count":10,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":29,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":12,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":7,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":14,"coverage":"discussed","id":"A1","source_count":7,"title":"Mechanistic promise and component attribution"},{"claim_count":14,"coverage":"discussed","id":"A2","source_count":4,"title":"Carboplatin omission and individualized use"},{"claim_count":24,"coverage":"discussed","id":"A3","source_count":17,"title":"Reception, adoption thresholds and access"},{"claim_count":22,"coverage":"discussed","id":"A4","source_count":3,"title":"DESTINY-Breast11 comparisons and residual-disease strategy"},{"claim_count":2,"coverage":"discussed","id":"A5","source_count":2,"title":"Wider HER2 development perspective"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":7,"cited_clinicians":7,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":6},"cited_physicians":7,"cited_sources":22,"claims_by_expression_type":{"comparison":11,"interpretation":28,"opinion":25,"primary_context":3,"question":4,"restatement":14,"uncertainty":10,"unspecified":9},"claims_by_kind":{"interpretation":1,"objective_result":2,"protocol_statement":1,"publication_statement":18,"source_observation":82},"clinician_statements":13,"evidence_units":108,"findings":10,"organisational_accounts":4,"people_cited":16,"people_identity_verified":15,"people_total":16,"screened_sources":43,"verified_claims":104},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":7,"views":13},"limitations":4,"links":{"context":3,"support":25},"ma_question":true,"named_voices":10,"passages":21,"sources":14,"sources_by_kind":{"commentary":12,"media":1,"publication":1}},"title":"Neo-Healer: some speakers want more data; some see practice-change potential","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-5434aefecc37f90e38ad","claim-6c629fdf94152f6a438e","claim-867c1fb5ae8d327dae78"],"clause":"some see practice-change potential","holders":3},"cited_claim_ids":["claim-6f81eda3fc051daa89a7","claim-d5b9d8e7a82c14ddd6d4","claim-867c1fb5ae8d327dae78","claim-0ce2ceb3c12920b1b578","claim-ad2fbdeff5243fec6263","claim-83e270642106ee36991d","claim-57de31b0392d9b9174f5","claim-e45afc019f7bcb426ed2-07197d05"],"clinicians":false,"holders":5,"speakers":10,"view":"reading"},"evidence_line":"22 statements from 10 speakers in 14 sources, 1 of them a podcast or video","holder_line":"5 of the 10 named speakers in this finding hold this view; 3 of the 10 hold its caveat, “some see practice-change potential”"},{"cited_clinicians":6,"id":"F2","structure":{"claims":22,"claims_by_group":{"comparisons":3,"experience":0,"questions":3,"restated":5,"views":11},"limitations":3,"links":{"context":12,"support":37},"ma_question":true,"named_voices":7,"passages":34,"sources":11,"sources_by_kind":{"commentary":8,"media":2,"publication":1}},"title":"HER2 targeting: most speakers question attribution; some clinicians see possible gains","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-88c4cccc7fbefac0b098","claim-d75b7755994a3aba5725","claim-30a720b15dfd2aa912bc","claim-38df88d4e9b9ecb87824","claim-d13bbef1b6508f5f2e77"],"clause":"some clinicians see possible gains","holders":2},"cited_claim_ids":["claim-92d54a999f319f3f6169","claim-ca7122abdcb867b7eadf","claim-d75b7755994a3aba5725","claim-867c1fb5ae8d327dae78","claim-4116d67e0b0a50b2d56d","claim-30a720b15dfd2aa912bc","claim-17083e52515e2cc41998","claim-5e931dfa176ddeb9667c"],"clinicians":false,"holders":6,"speakers":7,"view":"reading"},"evidence_line":"22 statements from 7 speakers in 11 sources, 2 of them podcasts or videos","holder_line":"6 of the 7 named speakers in this finding hold this view; 2 of them hold its caveat, “some clinicians see possible gains”"},{"cited_clinicians":0,"id":"F3","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":10},"limitations":2,"links":{"context":12,"support":24},"ma_question":true,"named_voices":3,"passages":21,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"publication":1}},"title":"Carboplatin: what speakers say","evidence_line":"15 statements from 3 speakers in 5 sources, 1 of them a podcast or video"},{"cited_clinicians":2,"id":"F4","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":5},"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":5,"passages":11,"sources":7,"sources_by_kind":{"commentary":5,"media":1,"publication":1}},"title":"Neo-Healer: most speakers cite AE rates; one weighs a shorter non-ADC course","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-250e537d3b65c189fa55"],"clause":"one weighs a shorter non-ADC course","holders":1},"cited_claim_ids":["claim-8ba0ad4a724daf6914a6","claim-6207eff6fc135b4cf03c","claim-22035f6b5f873aceda68","claim-867c1fb5ae8d327dae78","claim-ad2fbdeff5243fec6263","claim-473952eba2972c583150"],"clinicians":false,"holders":4,"speakers":5,"view":"reading"},"evidence_line":"11 statements from 5 speakers in 7 sources, 1 of them a podcast or video","holder_line":"4 of the 5 named speakers in this finding hold this view; 1 of the 5 holds its caveat, “one weighs a shorter non-ADC course”"},{"cited_clinicians":0,"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":5,"experience":0,"questions":1,"restated":1,"views":2},"limitations":4,"links":{"context":5,"support":15},"ma_question":true,"named_voices":2,"passages":13,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"Neo-Healer/DB11: what speakers say","evidence_line":"9 statements from 2 speakers in 4 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":3,"views":4},"limitations":4,"links":{"context":3,"support":13},"ma_question":true,"named_voices":4,"passages":13,"sources":9,"sources_by_kind":{"commentary":6,"media":2,"publication":1}},"title":"Beyond China: some speakers seek validation; one questions Western access","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-fdce70acd3f16e9a0c7b","claim-2fe0e48dfe97cef65408","claim-0db9bd7dbd5309834b91","claim-48302319159763413b24"],"clause":"one questions Western access","holders":1},"cited_claim_ids":["claim-6f81eda3fc051daa89a7","claim-0ce2ceb3c12920b1b578"],"clinicians":false,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"12 statements from 4 speakers in 9 sources, 2 of them podcasts or videos","holder_line":"2 of the 4 named speakers in this finding hold this view; 1 of the 4 holds its caveat, “one questions Western access”"},{"cited_clinicians":0,"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":1},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Payload-free backbone: a speaker asks if it could reserve T-DXd for residual disease","title_holders":{"cited_claim_ids":["claim-fdce70acd3f16e9a0c7b"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":0,"id":"F8","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":6},"limitations":3,"links":{"context":14,"support":16},"ma_question":true,"named_voices":0,"passages":16,"sources":1,"sources_by_kind":{"media":1}},"title":"Regimen: a speaker risk-adapts; one wants long-term T-DXd data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-33b8e8330c35fdac5d9c","claim-5d2cc458f2de034ce88e","claim-59cecf28fbd932cdb83b"],"clause":"one wants long-term T-DXd data","holders":0},"cited_claim_ids":["claim-6d497b854e8fc1e40844","claim-8fc6b68da78f25838608"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"10 statements in 1 source, a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F9","population":"beyond","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":4},"limitations":3,"links":{"context":8,"support":12},"ma_question":true,"named_voices":0,"passages":11,"sources":1,"sources_by_kind":{"media":1}},"title":"T-DXd×4: a speaker awaits RFS/OS; one leans on other evidence","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-bd76169492cbcd5470e1","claim-0afc61c76ef0833ee698"],"clause":"one leans on other evidence","holders":0},"cited_claim_ids":["claim-33b8e8330c35fdac5d9c","claim-5d2cc458f2de034ce88e","claim-59cecf28fbd932cdb83b"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"8 statements in 1 source, a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":1,"id":"F10","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Neo-Healer: a clinician sees a possible GI preview; one notes HER2 advances","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-0d8c0894a7a6c71603b6","claim-5d6dd0b5f9b65c25ba8b"],"clause":"one notes HER2 advances","holders":1},"cited_claim_ids":["claim-0d8c0894a7a6c71603b6"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 2 sources, 1 of them a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of the 1 holds its caveat, “one notes HER2 advances”"}],"open_question":{"basis":"From finding F1 (22 statements from 10 speakers in 14 sources)","cited_claim_ids":["claim-6f81eda3fc051daa89a7","claim-5434aefecc37f90e38ad","claim-d5b9d8e7a82c14ddd6d4","claim-6c629fdf94152f6a438e","claim-867c1fb5ae8d327dae78","claim-0ce2ceb3c12920b1b578","claim-ad2fbdeff5243fec6263","claim-83e270642106ee36991d","claim-60b99c13575ef28c0486","claim-57de31b0392d9b9174f5","claim-4b61ba082402f9288026","claim-36f90c4265012a80dd5a","claim-c58143e61f3af83abf96","claim-f52fe19d8a2d4609c7a0","claim-e45afc019f7bcb426ed2-07197d05"],"finding_ids":["F1"],"question":"What do clinicians say they need to see on EFS/OS, the contribution of different taxanes and Western validation before considering neoadjuvant anbenitamab plus HB1801, with or without carboplatin, a new standard for stage II–III HER2-positive breast cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"What evidence do speakers require before changing practice after Neo-Healer?"},{"id":"section-2","level":2,"title":"Two X accounts entertain stronger HER2 blockade; several accounts question component attribution"},{"id":"section-3","level":2,"title":"One author favors dropping carboplatin; a panel discussion leaves omission conditional on long-term evidence"},{"id":"section-4","level":2,"title":"Several accounts welcome tolerability; one highlights a payload-free antibody and shorter course"},{"id":"section-5","level":2,"title":"One X account distinguishes DB11; replacement of sequential T-DXd then THP is doubted in one video"},{"id":"section-6","level":2,"title":"Several accounts seek validation beyond China; Western use is considered hypothetical in one video"},{"id":"section-7","level":2,"title":"One X account asks whether a payload-free backbone could preserve T-DXd for residual disease"},{"id":"section-8","level":2,"title":"One discussion describes risk-adapted THP or sequential T-DXd then THP, with selective carboplatin use"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"One discussion questions long-term benefit from four neoadjuvant T-DXd cycles"},{"id":"section-11","level":3,"title":"One author sees a GI-oncology preview; a panel discussion sees continued room for HER2 advances"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":9},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3}],"id":"T1","label":"Primary endpoint: tpCR (BIRC, AJCC 8th)"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":5},{"id":"F8","shared_claims":3}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":16},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":7},{"id":"F6","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":8},{"id":"F5","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":2},{"id":"F6","shared_claims":5}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T20:48:19.477781Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T21:01:01Z","record_hash":"93eeb7dce28d0876e72a3e561eb87259c01065eb9b2460b01e64eca912f597d1","release_hash":"f1f08e42df26e2c2ed6bb58ce7e7fc941a0b89ca6050a9d2498b4880318dd7f9","report_id":"erudio-nct06747338","run_id":"c48b9d4f-958e-45e2-9173-1b7b6dd77e1b","schema_version":"5.0","slug":"neo-healer-nct06747338","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist thinks Neo-Healer could change treatment because of its response gain, but still awaits survival results. Another speaker sees potential for use in Asia while seeking evidence of applicability to other ethnicities. Medical oncologists question how much of the gain reflects HER2 blockade rather than nab-docetaxel; one also requires independent development and Western validation before adoption.","examples":[],"meta_description":"43 sources screened · 104 verified statements (13 from clinicians verified by NPI or staff page) from 22 sources · 10 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T21:01:01Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":43},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","43 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 18 sources about other trials or topics are not included.","The sources reviewed do not establish the prevalence of any view among HCPs, and source counts or reposts cannot be treated as independent clinician endorsement.","Several video statements cannot be assigned to a named speaker. Publisher participant lists and professional profiles do not establish who made those statements.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Relevant discussion may be missing when it never names the trial, uses unexpected spelling or addresses the same treatment decision without recognizable study terminology. One additional X conversation could not be assessed.","No separate protocol was available. The regulatory material reviewed was incomplete, and no exact KN026 or HB1801 label was located; the report does not establish comprehensive approval or availability status.","Early endpoint-announcement reactions, later numerical-result commentary and subsequent panel recollections have different information contexts. Their dates do not establish a change of mind.","Cross-study pCR and toxicity comparisons do not establish comparative superiority. The sources’ population, comparator and exposure-duration qualifications remain essential.","The unexplained negative reply and the unspecified questions relayed from a discussant cannot support more specific objections than the text provides."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":21,"results":1},"count":22,"evidence_window":{"end":"2026-11-05","start":"2026-04-01"},"retrieval_snapshot":"2026-11-20T16:23:40.442966Z","timeline":[{"count":2,"week":"2026-W14"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W20"},{"count":9,"week":"2026-W22"},{"count":1,"week":"2026-W34"},{"count":3,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W45"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06747338:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06747338:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42690668","quote_policy":"no_derivatives"},{"id":"openfda:27dd5e6b-72cd-458d-a015-cf4dab5800da:20260923","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mdlcbvaeudqgcmcai6536voq-3muctls4io22q","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7466594298600357888","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7501432653074673665","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2039255903040675999:76eb5a33-ae92-427c-babe-8c537e791bca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2039388159016902733:1b5981d4-cb7f-4801-925c-4caafd991176","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2039645787009757555:60f18bfc-0f29-46c8-96b8-ed9fcab3586b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2040397724231614496:6241b421-9889-4b71-94e8-d007bd223943","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2041516350506516601:878db60b-97a7-4554-a40a-01b12ef7f274","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056134104631107760:c937ff6a-2fae-403b-b668-3b7d62fe2679","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056716093738389862:8180ff4a-979f-43cf-a7c9-216ed9d478a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059736117231202738:1748cd44-57b0-45d8-b8e9-375bd3a9bffc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060825887864762483:4fb81632-8e1c-4bb6-9b39-7eb348458494","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060826118056227110:61b190cb-d297-438a-b787-7fe7034102a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060826988005511283:235e589f-72f8-435b-bdf0-65740420411a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060827280193036518:942ab0a9-1a12-4d5b-9bf2-f72437077c70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060827688315617385:86b6c2d5-54b2-455b-bfa9-903d419fabc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060828409081581803:fff46d0f-c8fa-4293-9f1e-f322ccd4650d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060829270230888777:9819931f-5232-47fc-8be2-81940d3287e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060830092658381001:9d747550-30bd-4d5c-b6ca-8756e88f1801","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060830141559853426:cd7a8937-326a-4096-b54d-7eb4cb81d0c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060833014658310484:9e706004-a953-43c9-aa96-3bb0b5f9eaa5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060834501601669584:415375dd-fc0d-412b-839b-d9ca027d91b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060836539379118126:38cec5db-f44e-49e4-9d79-bb5f6729f9fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060909462437888304:85657824-66e5-4079-a0e9-810c454ca6ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061044849390817638:360f2276-8805-4c3e-b714-49e06494efd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061064923916963955:8eb64756-d320-45ac-9d09-df2f5f125c7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062883174485487911:4cf1e414-c7dc-4bf8-9273-c93099e6e031","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064018623661035876:e964f33c-71d0-489a-8560-7365c0dc9eda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064281517250269320:d8fd47ed-da68-4f69-9792-6f67842c7d62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094047486650307030:5cf2b830-e607-4e87-94de-1141c44ebcb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095655201176801337:a4d299e3-5713-41cd-81b3-d2b43896ed87","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095897173959266413:bb861cc1-db49-4119-b747-550800cc1db5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096362063853666474:12db539f-c7e4-4849-8bf0-f81a3507d016","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096991885399105895:cf9711de-4fcc-4d0d-aa0b-bc548e1b44a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098305290492121375:ded37837-5c29-411a-ae7c-f03e8eb0a56b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103036786482221347:d850a576-aad6-4919-8606-01ff9bd5f2fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103152844186542289:47a3ea21-0397-4037-8b01-cdc2cb2d39af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104681845484872124:774ff4d0-ff2a-40e2-a4ac-ffd78985a366","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105901724636479905:d3a3b699-e53b-41eb-8313-bbc773e8d41e","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GV4FF4u2GL0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Lkz2WJXZ8mg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:PL3s-peqGMg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:PsWBOCZVn2g","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":36,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":43},"count":43,"evidence_window":{"end":"2026-11-05","start":"2026-04-01"},"retrieval_snapshot":"2026-11-20T16:23:40.442966Z","timeline":[{"count":5,"week":"2026-W14"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":17,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":4,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":3,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":7,"other":0,"podcast":0,"publication":21,"registry":0,"regulatory":0,"x_thread":32,"x_video":0,"youtube":44}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"anbenitamab","slug":"anbenitamab"},{"reason":"Unmapped registry intervention: hb1801","status":"unmapped"},{"brand_names":["Perjeta"],"label":"pertuzumab","slug":"pertuzumab"},{"brand_names":["Herceptin"],"label":"trastuzumab","slug":"trastuzumab"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"}],"indications":[{"reason":"Unmapped registry condition: Early or Locally Advanced HER2-positive Breast Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"Neo-Healer","aliases":["Neo-Healer","A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer."],"brief_title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Early or Locally Advanced HER2-positive Breast Cancer"],"display_condition":"early or locally advanced HER2-positive breast cancer","display_interventions":[["anbenitamab","HB1801"]],"enrollment":{"count":520,"type":"ESTIMATED"},"interventions":[{"name":"KN026","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"HB1801","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pertuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Trastuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Docetaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06747338","official_title":"A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-12-16","type":"ESTIMATED"},"primary_endpoints":[{"description":"tpCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy.","measure":"tpCR (BIRC, AJCC 8th)","timeFrame":"Through study completion, an average of 1 year"}],"registered_date":{"date":"2024-12-24","type":"ACTUAL"},"registry_last_updated":"2026-07-07","registry_url":"https://clinicaltrials.gov/study/NCT06747338","short_name":"Neo-Healer","short_name_basis":"registry_acronym","sponsor":"Shanghai JMT-Bio Inc.","start_date":{"date":"2024-12-16","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"KN026-004","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}